Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201 for Advanced Solid Tumors

on

Repertoire Immune Medicines announced on April 23, 2026, that the first participant has been dosed in a Phase 1/2 clinical trial of RPTR-1-201, a novel TCR bispecific therapy for advanced solid tumors.1

The trial evaluates safety, tolerability, and preliminary antitumor activity as monotherapy and in combination with anti-PD-1, conducted at sites in the US and Europe after FDA IND clearance and European CTIS authorization.1

RPTR-1-201, the first asset from Repertoire's DECODE platform to enter human trials, targets a novel tumor-selective epitope shared across multiple solid tumors, potentially relevant for 200,000 patients annually in the US and Europe.1

Preclinical studies showed potent killing of 'hot' and 'cold' tumors with a favorable safety profile; trial identifier is NCT07293754 on clinicaltrials.gov.110

Sources:

1. https://www.biospace.com/press-releases/repertoire-immune-medicines-announces-first-participant-dosed-in-phase-1-2-trial-of-rptr-1-201-a-t-cell-targeted-immune-medicine-for-advanced-solid-tumors

10. https://clinicaltrials.gov/study/NCT07293754